Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation

Cardiovascular Research

Volumn 89, Issue 2, 2011, Pages 273-281

  Talha, Samy ^a   Charloux, Anne ^a   Enache, Irina ^a   Piquard, François ^a   Geny, Bernard ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Haemodynamics; Inflammation; Natriuretic peptides; Transplantation

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYCLOSPORIN; PREDNISONE;

ACUTE GRAFT REJECTION; CARDIAC ALLOGRAFT VASCULOPATHY; CORTICOSTEROID THERAPY; DIASTOLIC DYSFUNCTION; DRUG DOSE REDUCTION; HEART DENERVATION; HEART TRANSPLANTATION; HEART VENTRICLE FUNCTION; HEART VENTRICLE PRESSURE; HEART VENTRICLE WALL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FAILURE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; REVIEW; SYSTOLIC DYSFUNCTION; WALL STRESS;

ANIMALS; BIOLOGICAL MARKERS; HEART FAILURE; HEART TRANSPLANTATION; HUMANS; INFLAMMATION MEDIATORS; NATRIURETIC PEPTIDE, BRAIN; TREATMENT OUTCOME; UP-REGULATION;

EID: 78751526447     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq331     Document Type: Review

References (99)

1. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000;2:198-205.
2. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-588.
3. Adams KF Jr, Mathur VS, Gheorghiade M. B-type natriuretic peptide: from bench to bedside. Am Heart J 2003;145:S34-S46.
4. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PG et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002;106:416-422.
5. Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, Moriguchi M et al. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol 2008;51:2329-2335.
6. Boerrigter G, Costello-Boerrigter LC, Burnett JC Jr. Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin 2009;5:501-514.
7. Buckley MG, Sethi D, Markandu ND, Sagnella GA, Singer DRJ, MacGregor GA. Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure. Clin Sci 1992; 83:437-444.
8. Geny B, Follenius M, Epailly E, Charpentier A, Brandenberger G, Eisenmann B et al. Transient reduction without normalization of brain natriuretic peptide early after heart transplantation. J Thorac Cardiovasc Surg 1998;115:473-475.
9. Hervas I, Arnau MA, Almenar L, Pérez-Pastor JL, Chirivella M, Osca J et al. Ventricular natriuretic peptide (BNP) in heart transplantation: BNP correlation with endomyocardial biopsy, laboratory and hemodynamic measures. Lab Invest 2004;84:138-145.
10. El Gamel A, Yonan NA, Keevil B, Warbuton R, Kakadellis J, Woodcock A et al. Significance of raised natriuretic peptides after bicaval and standard cardiac transplantation. Ann Thorac Surg 1997;63:1095-1100.
11. Arnau-Vives MA, Almenar L, Hervas I, Osa A, Martinez-Dolz L, Rueda J et al. Predictive value of brain natriuretic peptide in the diagnosis of heart transplant rejection. J Heart Lung Transplant 2004;23:850-856.
12. Hervas I, Almenar L, Perez-Pastor JL, Chirivella M, Osa A, Martínez-Dolz L et al. Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determinations and biopsy grading of rejection. Nucl Med Commun 2003;24:925-931.
13. Geny B, Hardy H, Lonsdorfer J, Eisenmann B, Haberey P, Piquard F. Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients. Hypertension 1999;33:969-974.
14. Buckley MG, Yacoub MH, Singer DR. Investigation of the plasma concentrations and circulating forms of BNP and ANP in orthotopic cardiac transplant recipients. J Hum Hypertens 1998;12:825-826.
15. O'Neill JO, McRae AT III, Troughton RW, Troughton RW, Ng K, Starling RC. Brain natriuretic peptide levels do not correlate with acute cellular rejection in de novo orthotopic heart transplant recipients. J Heart Lung Transplant 2005;24:416-420.
16. Almenar L, Arnau MA, Martínez-Dolz L, Hervás I, Osa A, Miró V et al. Is there a correlation between brain natriuretic peptide levels and echocardiographic and hemodynamic parameters in heart transplant patients? Transplant Proc 2006;38:2534-2536.
17. Wu AH, Johnson ML, Aaronson KD, Gordon D, Dyke DBS, Koelling TM. Brain natriuretic peptide predicts serious cardiac allograft rejection independent of hemodynamic measurements. J Heart Lung Transplant 2005;24:52-57.
18. Klingenberg R, Koch A, Gleissner C, Schnabel PA, Haass M, Remppis A et al. Determinants of B-type natriuretic peptide plasma levels in the chronic phase after heart transplantation. Transpl Int 2005;18:169-176.
19. Park MH, Scott RL, Uber PA, Harris BC, Chambers R, Mehra MR. Usefulness of B-type natriuretic peptide levels in predicting hemodynamic perturbations after heart transplantation despite preserved left ventricular systolic function. Am J Cardiol 2002;90:1326-1329.
20. Uber PA, Mehra MR, Harris B, Scott RL, Park MH. Steroid weaning in heart transplantation is associated with decreased B-type natriuretic peptide: surrogate evidence for cardiac adaptation. Transplant Proc 2002;34:1843-1844.
21. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-208. (Pubitemid 28064743)
22. Reesink HJ, Tulevski II, Marcus JT, Boomsma F, Kloek JJ, Vonk Noordegraaf A et al. Brain natriuretic peptide as noninvasive marker of the severity of right ventricular dysfunction in chronic thromboembolic pulmonary hypertension. Ann Thorac Surg 2007; 84:537-543.
23. Yap LB, Ashrafian H, Mukerjee D, Coghlan JG, Timms PM. The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension. Clin Biochem 2004;37:847-856.
24. Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43:764-770. (Pubitemid 38296473)
25. Goette Di Marco P, Talha S, Enache I, Weiller M-A, Charloux A, Massard G et al. Endocrine heart after lung transplantation: increased brain natriuretic peptide is related to right ventricular function. Transpl Int 2010;23:728-735.
26. Garrido IP, Pascual-Figal DA, Nicolás F, González-Carrillo MJ, Manzano-Fernández S, Sánchez-Mas J et al. Usefulness of serial monitoring of B-type natriuretic peptide for the detection of acute rejection after heart transplantation. Am J Cardiol 2009;15: 1149-1153.
27. Bader FM, Rogers RK, Kfoury AG, Gilbert EM, Horne BD, Stehlik J et al. Timedependent changes in B-type natriuretic peptide after heart transplantation: correlation with allograft rejection and function. Congest Heart Fail 2009;15:63-67.
28. Masters RG, Davies RA, Keon WJ,Walley VM, Koshal A, de Bold AJ. Neuroendocrine response to cardiac transplantation. Can J Cardiol 1993;9:609-617.
29. Geny B, Piquard F, Follenius M, Thiranos JC, Charpentier A, Epailly E et al. Endothelin participates in increased circulating atrial natriuretic peptide early after human heart transplantation. J Heart Lung Transplant 1998;17:167-175.
30. Ationu A, Burch M, Singer D, Littleton P, Carter N. Cardiac transplantation affects ventricular expression of brain natriuretic peptide. Cardiovasc Res 1993;27:188-191. (Pubitemid 23070326)
31. Kirchhoff WCh, Gradaus R, Stypmann J, Deng MC, Tian TD, Scheld HH et al. Vasoactive peptides during long-term follow-up of patients after cardiac transplantation. J Heart Lung Transplant 2004;23:284-288.
32. Ogawa T, Veinot JP, Davies RA, Haddad H, Smith SJ, Masters RG et al. Neuroendocrine profiling of humans receiving cardiac allografts. J Heart Lung Transplant 2005;24: 1046-1054.
33. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003;89:875-878.
34. Ationu A, Sorensen K, Whitehead B, Singer D, Burch M, Carter ND. Ventricular expression of brain natriuretic peptide gene following orthotopic cardiac transplantation in children-a three-year follow up. Cardiovasc Res 1993;27:2135-2139.
35. Lan YT, Chang RK, Alejos JC, Burch C, Wetzel GT. B-type natriuretic peptide in children after cardiac transplantation. J Heart Lung Transplant 2004;23:558-563.
36. Guyton AC, Hall JE. Textbook of Medical Physiology. 10th ed. Philadelphia, PA: W.B. Saunders Company; 2000.
37. McGrath MF, de Bold ML, de Bold AJ. The endocrine function of the heart. Trends Endocrinol Metab 2005;16:469-477.
38. Brandt I, Lambeir AM, Ketelslegers JM, Vanderheyden M, Scharpé S, De Meester I. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin Chem 2006;52:82-87.
39. Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide: from bench to bedside. Clin Chem Lab Med 2009;47:248-252.
40. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007;292:R897-R901.
41. Vanderheyden M, Vrints C, Verstreken S, Bartunek J, Beunk J, Goethals M. B-type natriuretic peptide as a marker of heart failure: new insights from biochemistry and clinical implications. Biomark Med 2010;4:315-320.
42. Mehra MR, Uber PA, Potluri S, Ventura HO, Scott RL, Park MH. Usefulness of an elevated B-type natriuretic peptide to predict allograft failure, cardiac allograft vasculopathy, and survival after heart transplantation. Am J Cardiol 2004;15:454-458.
43. Mehra MR, Uber PA, Walther D, Vesely M, Wohlgemuth JG, Prentice J et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker. Circulation 2006;114:I21-I26.
44. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41:571-579.
45. Geny B, Piquard F, Follenius M, Mettauer B, Schaefer A, Canguilhem B et al. Role of cardiac innervation in atrial natriuretic peptide secretion in transplanted heart recipients. Am J Physiol 1993;265:F112-F118.
46. Geny B, Charloux A, Lampert E, Lonsdorfer J, Haberey P, Piquard F. Enhanced brain natriuretic peptide response to peak exercise in heart-transplant recipient. J Appl Physiol 1998;85:2270-2276.
47. Geny B, Richard R, Mettauer B, Lonsdorfer J, Piquard F. Cardiac natriuretic peptides during exercise and training after heart transplantation. Cardiovasc Res 2001;51: 521-528.
48. Geny B, Saini J, Mettauer B, Lampert E, Piquard F, Follenius M et al. Effect of short term endurance training on exercise capacity, hemodynamics and atrial natriuretic peptide secretion in heart transplant recipients. Eur J Appl Physiol Occup Physiol 1996;73:259-266.
49. Talha S, Di Marco P, Doutreleau S, Rouyer O, Piquard F, Geny B. Does circulating BNP normalize after heart transplantation in patients with normal hemodynamic and right and left heart functions? Clin Transplant 2008;22:542-548.
50. Braith RW, Mills RM Jr, Wilcox CS, Davis GL, Wood CE. Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients. J Am Coll Cardiol 1996;27:375-383.
51. Piquard F, Geny B, Elero B, Canguilhem B, Mettauer B, Epailly E et al. Role of immunosuppressive therapy in neuroendocrine activation after human heart, renal, and liver transplantation. Transplant Proc 1998;30:2124-2126.
52. Schwietzer GK, Hartmann A, Kober G, Jungmann E, Stratmann D, Kaltenbach M et al. Chronic angiotensin-converting enzyme inhibition may improve sodium excretion in cardiac transplant hypertension. Transplantation 1995;59:999-1004.
53. Geny B, Piquard F, Lonsdorfer J, Haberey P. Endothelin and heart transplantation. Cardiovasc Res 1998;39:556-562.
54. Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997;12:375-381.
55. Mehra MR, Uber PA, Park MH, Ventura HO, Scott RL. Corticosteroid weaning in the tacrolimus and mycophenolate era in heart transplantation: clinical and neurohormonal benefits. Transplant Proc 2004;36:3152-3155.
56. Mehra MR, Milani RV, Richie MB, Uber PA, Park MH, Ventura HO et al. Ventricularvascular uncoupling increases expression of B-type natriuretic peptide in heart transplantation. Transplant Proc 2004;36:3149-3151.
57. Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation 2004;110:1794-1798.
58. Nickel T, Schlichting CL, Weis M. Drugs modulating endothelial function after transplantation. Transplantation 2006;82:S41-S46.
59. Richard R, Zoll J, Mettauer B, Piquard F, Geny B. Cardiac denervation does not play a major role in exercise limitation after heart transplantation. J Appl Physiol 2008;104: 560-562.
60. Schaefer A, Piquard F, Doutreleau S, Mettauer B, Epailly E, Eisenmann B et al. Reduced exercise capacity is associated with reduced nitric oxide production after heart transplantation. J Thorac Cardiovasc Surg 2001;122:821-822.
61. Talha S, Rouyer O, Doutreleau S, Di Marco AP, Kindo M, Richard R et al. Exercise-induced increase in brain natriuretic peptide is related to vascular endothelial function after heart transplantation. J Heart Lung Transplant 2007;26: 1075-1076.
62. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Aurora P, Christie J et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Heart Transplant Report 2007. J Heart Lung Transplant 2007;26:769-781. (Pubitemid 47199081)
63. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report 2009. J Heart Lung Transplant 2009;28:1007-1022.
64. Hornick P, Rose M. Chronic rejection in the heart. Methods Mol Biol 2006;333: 131-144.
65. Lindblade CL, Chun DS, Darragh RK, Caldwell RL, Murphy DJ, Schamberger MS. Value of plasma B-type natriuretic peptide as a marker for rejection in pediatric heart transplant recipients. Am J Cardiol 2005;95:909-911.
66. De Bold AJ, Bruneau BG. Natriuretic peptides. In: Fray JCS, Goodman MH, eds. Handbook of Physiology. Section 7. The Endocrine System. Vol. III. Endocrine Regulation of Water and Electrolyte Balance. New York: American Physiological Society by Oxford University Press; 2000.
67. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002;50:799-809.
68. Shaw SM, Williams SG. Is brain natriuretic peptide clinically useful after cardiac transplantation. J Heart Lung Transplant 2006;25:1396-1401.
69. Masters RG, Davies RA, Veinot JP, Hendry PJ, Smith SJ, De Bold AJ. Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans. Circulation 1999;100:287-291.
70. Almenar L, Hervas I, Martinez-Dolz L, Rueda J, Arnau MA, Osa A et al. The value of brain natriuretic peptide for the diagnosis of heart transplant rejection. Transplant Proc 2002;34:174-175.
71. Hammerer-Lercher A, Mair J, Antretter H, Ruttmann E, Poelzl G, Laufer G et al. B-type natriuretic peptide as a marker of allograft rejection after heart transplantation. J Heart Lung Transplant 2005;24:1444e5-1444e8.
72. Behera SK, Trang J, Feeley BT, Levi DS, Alejos JC, Drant S. The use of Doppler tissue imaging to predict cellular and antibody-mediated rejection in pediatric heart transplant recipients. Pediatr Transplant 2008;12:207-214.
73. Geiger M, Harake D, Halnon N, Alejos JC, Levi DS. Screening for rejection in symptomatic pediatric heart transplant recipients: the sensitivity of BNP. Pediatr Transplant 2008;12:563-569.
74. Rossano JW, Denfield SW, Kim JJ, Price JF, Jefferies JL, Decker JA et al. B-type natriuretic peptide is a sensitive screening test for acute rejection in pediatric heart transplant patients. J Heart Lung Transplant 2008;27:649-654.
75. Wallace CK, Stetson SJ, Küçüker SA, Becker KA, Farmer JA, McRee S et al. Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients. J Heart Lung Transplant 2005;24:46-51.
76. Kobashigawa JA, Moriguchi JD, Laks H, Wener L, Hage A, Hamilton MA et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005;24:1736-1740.
77. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L,Wang XM et al. Effect of pravastatin on outcome after cardiac transplantation. N Engl J Med 1995;333:621-627.
78. Landmesser U, Wollert KC, Drexler H. Potential novel pharmacological therapies for myocardial remodeling. Cardiovasc Res 2009;81:519-527.
79. De Sylos C, Azeka E, Kajita L, Benvenutti L, Strunz CC, Branco KC et al. B-type natriuretic peptide assessment in the diagnosis of rejection after pediatric heart transplant. Arq Bras Cardiol 2009;92:215-226.
80. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E et al. HOPE Study Investigators. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006;114:201-208.
81. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-534.
82. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-241.
83. Vaz Pérez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD et al. The relationship between tumor necrosis factor-alpha, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2010;141:39-43.
84. Nozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J 1997;61:657-664.
85. Solus J, Chung CP, Oeser A, Avalos I, Gebretsadik T, Shintani A et al. Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 2008;58:2662-2669.
86. Provan SA, Angel K, Odegärd S, Mowinckel P, Atar D, Kvien TK. The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther 2008;10:R70.
87. Ma KK, Ogawa T, De Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol 2004;36:505-513.
88. Duquesnoy RJ, Demetris AJ. Immunopathology of cardiac transplant rejection. Curr Opinion Cardiol 1995;10:193-206.
89. Bruggink AH, De Jonge N, Van Oosterhout MF, Van Wichen DF, de Koning E, Lahpor JR et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist. J Heart Lung Transplant 2006;25:174-180.
90. He Q, Lapointe MC. Interleukine-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999;33:283-289.
91. He Q, Lapointe MC. Interleukine-1beta regulates the human brain natriuretic peptide promoter via Ca2+-dependent protein kinase pathways. Hypertension 2000;35: 292-296.
92. Tsuruda T, Boerrigter G, Huntley BK, Noser JA, Cataliotti A, Costello-Boerrigter LC et al. Brain natriuretic peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 2002;91:1127-1134.
93. Tomaru Ki K, Arai M, Yokoyama T, Aihara Y, Sekiguchi Ki K, Tanaka T et al. Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002;34:649-659.
94. Vesely DL, de Bold AJ. Cardiac natriuretic peptides gene expression and secretion in inflammation. J Investig Med 2009;57:29-32.
95. Meirovich YF, Veinot JP, de Bold ML, Haddad H, Davies RA, Masters RG et al. Relationship between natriuretic peptides and inflammation:proteomic evidence obtained during acute cellular cardiac allograft rejection in humans. J Heart Lung Transplant 2008;27:31-37.
96. Hare JM, Baughman KL, Kass DA, Goodman SN, Ladenson PW. Influence of dilated cardiomyopathy, myocarditis and cardiac transplantation on the relation between plasma atrial natriuretic factor and atrial pressures. Am J Cardiol 1991;67:391-397.
97. Ogawa T, Veinot JP, Kuroski de Bold ML, Georgalis T, de Bold AJ. Angiotensin II receptor antagonism reverts the selective cardiac BNP upregulation and secretion observed in myocarditis. Am J Physiol Heart Circ Physiol 2008;294:H2596-H2603.
98. Torre-Amione G, MacLellan W, Kapadia S, Weilbaecher D, Farmer J, Young J et al. Tumor necrosis factor-alpha is persistently expressed in cardiac allografts in the absence of histological or clinical evidence of rejection. Transplant Proc 1998;30: 875-877.
99. Shaw SM, Fildes JE, Puchalka CM, Basith M, Yonan N, Williams SG. BNP directly immunoregulates the innate immune system of cardiac transplant recipients in vitro. Transpl Immunol 2009;20:199-202.